FDA’s liquid biopsy approval is a milestone for Guardant Health AMEA: CEO
5 years ago 1 min read
Simranjit Singh, CEO of Guardant Health AMEA, talks to “Squawk Box Asia” about obtaining the U.S. Food and Drug Administration’s first liquid biopsy approval that can help in cancer detection and treatment.
More Stories
Record Korean Cases; Trader’s Guide to Rollout: Virus Update
California Hits Record; Trader’s Guide to Rollout: Virus Update
AstraZeneca to Buy Alexion for $39 Billion in Rare-Disease Push